Correlates of protective immunity to HCV and rational vaccine design: Project 3
HCV 保护性免疫与合理疫苗设计的相关性:项目 3
基本信息
- 批准号:10608113
- 负责人:
- 金额:$ 95.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-15 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAntibody ResponseAntigensB-LymphocytesBloodCD8-Positive T-LymphocytesCellular ImmunityCombined VaccinesComparative StudyDNADevelopmentGenotypeGlycoproteinsGoalsHIVHIV vaccineHelper-Inducer T-LymphocyteHepatitis CHepatitis C virusHumanHumoral ImmunitiesImmune responseImmunityImmunizationIn VitroInfectionInfection preventionLiverMembraneModalityModified Vaccinia Virus AnkaraMolecularNonstructural ProteinPersonsPreventive vaccineProteinsRecombinantsRegimenReportingRoleSeriesSiteStructureT cell responseT-LymphocyteTNFSF5 geneTestingTissuesVaccinationVaccine DesignVaccinesViralViral AntigensViral ProteinsVirionVirus DiseasesVirus ReplicationVirus-like particleantiviral immunitycross reactivitydelivery vehicledesignexperienceimprovedinsightneutralizing antibodynonhuman primatepreservationprospectiveprotein expressionresponsevaccination strategyvaccine trialvirus core
项目摘要
Hepatitis C virus (HCV) continues to infect ~71 million people worldwide with an estimated 1.5 to 2 million new
infections each year. A complete eradication of HCV infection warrants development of an effective vaccine that
can rapidly induce a durable anti-viral immunity and prevent infection. Evidence from spontaneous controllers
suggests that a broad and durable HCV-specific CD4 and CD8 T cell responses are critical for effective control
of HCV infection. In addition, a protective role for neutralizing antibody against viral glycoproteins E1&E2 has
also been implicated. Furthermore, it is critical generate anti-viral immunity in the liver (the primary site of virus
replication). Thus, the primary goal of this proposal is to develop a vaccination strategy using DNA, modified
vaccinia Ankara (MVA), and protein-based vaccines that will generate a robust and broad HCV specific T and B
cell responses in blood and liver against multiple HCV proteins. We hypothesize that induction of a strong, broad,
and persistent T cell response against HCV antigens in the blood and liver combined with induction of strong
neutralizing antibody response will provide protection against HCV infection and different combinations of
DNA/MVA/protein vaccination can be harnessed to achieve the desired protective immunity. We propose to
achieve these objectives using 3 specific aims. In Aim 1 we will construct and characterize DNA and MVA
vaccines expressing HCV core, NS3-NS5 and E1E2 proteins. In Aim 2 we will optimize the DNA/MVA vaccine
modality for inducing strong T cell and antibody responses. The optimizations will include testing the E1E2 in
two forms either presented on the virus-like particle (VLP) or secreted. In addition, we will test the influence of
CD40L adjuvant on cellular and humoral immunity. In Aim 3 we will optimize E1E2 protein boosts for DNA/MVA
vaccine for further enhancing the antibody responses. By completion of these studies we hope generate an
optimal vaccine against HCV that induces strong T cell and neutralizing antibody responses.
丙型肝炎病毒(HCV)继续感染全球约7100万人,估计新增150万至200万人
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rama Rao Amara其他文献
Rama Rao Amara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rama Rao Amara', 18)}}的其他基金
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
预防和根除 SIV/SHIV 感染的 B 和 T 细胞生物学
- 批准号:
10462362 - 财政年份:2022
- 资助金额:
$ 95.72万 - 项目类别:
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
预防和根除 SIV/SHIV 感染的 B 和 T 细胞生物学
- 批准号:
10618319 - 财政年份:2022
- 资助金额:
$ 95.72万 - 项目类别:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
HCV 保护性免疫与合理疫苗设计的相关性:项目 3
- 批准号:
10393619 - 财政年份:2021
- 资助金额:
$ 95.72万 - 项目类别:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
HCV 保护性免疫与合理疫苗设计的相关性:项目 3
- 批准号:
10205769 - 财政年份:2021
- 资助金额:
$ 95.72万 - 项目类别:
Combined cytokine therapy for sustained HIV remission
联合细胞因子疗法可持续缓解艾滋病毒
- 批准号:
10348184 - 财政年份:2020
- 资助金额:
$ 95.72万 - 项目类别:
Combined cytokine therapy for sustained HIV remission
联合细胞因子疗法可持续缓解艾滋病毒
- 批准号:
10573329 - 财政年份:2020
- 资助金额:
$ 95.72万 - 项目类别:
Targeting PD-1 Pathway for Functional Cure of AIDS
靶向 PD-1 通路实现艾滋病功能性治愈
- 批准号:
10349439 - 财政年份:2019
- 资助金额:
$ 95.72万 - 项目类别:
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIV
MVA Prime/新型三聚体循环排列包膜蛋白增强 HIV 疫苗
- 批准号:
10449340 - 财政年份:2019
- 资助金额:
$ 95.72万 - 项目类别:
相似海外基金
The IgE Antibody Response to Dsg1 and Environmental Antigens in Endemic Pemphigus Foliaceus
地方性落叶型天疱疮中 IgE 抗体对 Dsg1 和环境抗原的反应
- 批准号:
9303192 - 财政年份:2015
- 资助金额:
$ 95.72万 - 项目类别:
The IgE Antibody Response to Dsg1 and Environmental Antigens in Endemic Pemphigus Foliaceus
地方性落叶型天疱疮中 IgE 抗体对 Dsg1 和环境抗原的反应
- 批准号:
9752473 - 财政年份:2015
- 资助金额:
$ 95.72万 - 项目类别:
The IgE Antibody Response to Dsg1 and Environmental Antigens in Endemic Pemphigus Foliaceus
地方性落叶型天疱疮中 IgE 抗体对 Dsg1 和环境抗原的反应
- 批准号:
8965123 - 财政年份:2015
- 资助金额:
$ 95.72万 - 项目类别:
REGULATION OF ANTIBODY RESPONSE TO BACTERIAL ANTIGENS
对细菌抗原的抗体反应的调节
- 批准号:
3221412 - 财政年份:1985
- 资助金额:
$ 95.72万 - 项目类别:
REGULATION OF ANTIBODY RESPONSE TO BACTERIAL ANTIGENS
对细菌抗原的抗体反应的调节
- 批准号:
3221413 - 财政年份:1985
- 资助金额:
$ 95.72万 - 项目类别:
REGULATION OF ANTIBODY RESPONSE TO BACTERIAL ANTIGENS
对细菌抗原的抗体反应的调节
- 批准号:
3221409 - 财政年份:1985
- 资助金额:
$ 95.72万 - 项目类别:
GENETIC CONTROL OF THE ANTIBODY RESPONSE TO MICROBIAL ANTIGENS
对微生物抗原的抗体反应的遗传控制
- 批准号:
4688363 - 财政年份:
- 资助金额:
$ 95.72万 - 项目类别:
GENETIC CONTROL OF THE ANTIBODY RESPONSE TO MICROBIAL ANTIGENS
对微生物抗原的抗体反应的遗传控制
- 批准号:
3803095 - 财政年份:
- 资助金额:
$ 95.72万 - 项目类别:
GENETIC CONTROL OF THE ANTIBODY RESPONSE TO MICROBIAL ANTIGENS
对微生物抗原的抗体反应的遗传控制
- 批准号:
3818114 - 财政年份:
- 资助金额:
$ 95.72万 - 项目类别:
REGULATION OF THE ANTIBODY RESPONSE TO MICROBIAL POLYSACCHARIDE ANTIGENS
微生物多糖抗原抗体反应的调节
- 批准号:
3821967 - 财政年份:
- 资助金额:
$ 95.72万 - 项目类别: